Cardiol Therapeutics Inc. - CRDL Net Assets per Single Share

Graphic logo of Cardiol Therapeutics Inc. (CRDL)

Cardiol Therapeutics (CRDL) growth is driven by partnerships with research centers to test new molecules. The projected book value per share visualizes this process, where 0.15 describes the current status of the metric. The business potential is based on the unique CardiolRx drug for treating pericarditis, while the focus on patients with chronic pathologies guarantees stable, multi-year demand for pharmaceuticals.

Accounting Value of a Share: Cardiol (CRDL) for 07/04/2022 - 10/28/2026

Cardiol Therapeutics Inc - analytical breakdowns and key metrics (CRDL)

- price and consensus price forecast:
Stock Price Cardiol|CRDL - Broker Consensus Forecast
- market capitalization data:
Market Value Cardiol Therapeutics Inc.|CRDL - Total Company Value
- book capitalization data:
Book Value per Share Cardiol Therapeutics|CRDL - Accounting Value of Company|Market Capitalization to Book Value Ratio cardiolrx.com|CRDL - Company Assets
- debt and liquidity data:
Total Debt to Capital Cardiol Therapeutics|CRDL - Long-Term Debt to Capital|Short-Term Debt to Equity Cardiol|CRDL - Aggregate Debt Obligations|Debt to Book Value Cardiol Therapeutics Inc.
Initial company analysis:CRDL (cardiolrx.com)
Manufactured products of Cardiol

To assess the credit quality of Cardiol Therapeutics (CRDL), the analyst examines the calculated book value per share, which reflects actual net assets per share excluding subjective valuations. Since the company fully outsources production and research, this indicator captures the actual financial stability of the business in the absence of proprietary plants, helping the investor balance fundamental protection and risks.

Competitors of Cardiol Therapeutics (CRDL)

Regeneron Inc. (REGN) - Book Value per Share|IRTC: Equity per Share|Lantheus Holdings, Inc. (LNTH) - Net Assets per Single Share|mineralystx.com (MLYS) - Net Assets per Single Share|HTFL - Book Value per Share|Accounting Value of a Share Kestra Medical Technologies, Inc.|Esperion Therapeutics Inc - Book Value per Share|Net Asset Value per Share Amarin Pharma (AMRN)|Book Value per Share AVR (Anteris Technologies)|Tenaya - Book Value per Share|Net Assets per Single Share CVRx (CVRX)|Milestone Pharmaceuticals, Inc. (MIST) - Accounting Value of a Share|BEAT - Accounting Value per Share|Tenax Therapeutics Inc (TENX) - Book Price of a Share|Book Value per Share ADGM|Accounting Value per Share biocardia.com|Book Value per Share VTAK|Book Value per Share ABIO (arcabio.com)|Net Assets per Single Share Acasti Pharma Inc.|Accounting Value of a Share Aerovate Therapeutics, Inc AVTE|Verve (VERV) - Book Value per Share|WINT - Equity per Share